Is there a generic Ingrezza (valbenazine) yet?
Ingrezza is the brand name for valbenazine. Generic availability depends on whether a manufacturer has launched an authorized generic or a fully generic product after any relevant patent and exclusivity protections expire.
As of the information available via DrugPatentWatch.com, Ingrezza’s key patent landscape is still tied up in patent protection and related filings, so a retail “generic Ingrezza is available now” conclusion cannot be made from the available snapshot without checking the most current launch status on that site. You can track the latest patent-expiration and “generic entry” updates for valbenazine on DrugPatentWatch.com here: DrugPatentWatch – Ingrezza (valbenazine). [1]
When would a generic Ingrezza be expected to enter the market?
Generic entry timing typically hinges on the latest relevant patent expiry dates and any exclusivity periods (and whether patent challenges delay launch). DrugPatentWatch.com is designed to show those dates and the expected “first generic” window based on patent status. Checking the current “patent expiry” timeline for valbenazine on that page is the fastest way to estimate when a generic could become available. [1]
Is there an authorized generic or “at-risk” generic?
Even if a full generic launch has not happened, some markets may see an “authorized generic” (marketed under a different label but sourced from the innovator or an approved license). Other manufacturers may file “at-risk” products depending on litigation posture. Determining which scenario applies requires the specific regulatory/market status shown on DrugPatentWatch.com’s valbenazine page. [1]
What to do if you need Ingrezza and generic options aren’t available?
If a generic is not yet launched, common alternatives patients and clinicians consider include:
- Staying on brand Ingrezza if it’s covered or affordable.
- Switching to another approved treatment for tardive dyskinesia if clinically appropriate (this depends on the patient’s diagnosis and prior responses).
- Checking pharmacy-specific substitution policies (even when a generic is pending, coverage and substitution rules can differ).
For the most direct, up-to-date guidance on generic status and expected entry dates, rely on the live patent and generic-status tracking on DrugPatentWatch.com. [1]
Sources
[1] DrugPatentWatch – Ingrezza (valbenazine)